In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic, Abbott Swap to Stay In Drug Stent Race

Executive Summary

Medtronic and Abbott Laboratories, both lagging in the race to develop drug-eluting stents, are teaming up to bolster their respective programs in that field. Medtronic lacks a viable anti-restenosis drug and a polymer coating, while Abbott doesn't have a delivery system. Yet, Medtronic has an over-the-wire delivery system and Abbott has a promising anti-proliferative agent in clinical trials. Together, the companies believe they can become viable players in what is sure to be a lucrative, albeit fiercely competitive market.
Advertisement

Related Content

World Congress of Cardiology: DES Safety Dominates Discussions
Turning Around Medtronic Vascular
Medtronic Licenses Early Stage Stent Drug to Prevent Thrombosis
Beyond Medical Devices: An Interview with Medtronic's Bill Hawkins
Next Drug Stent Trials: Medtronic Goes to Europe, Guidant Stays Home
Keeping Leadership Real: An Interview with Bill George

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel